Posted on December 1, 2021 |
By 340B Matters Despite Big Pharma’s efforts to eviscerate the 340B Drug Discount Program, recent federal court decisions have made it clear that manufacturers are acting illegally. Eli Lilly, ...
Posted on November 15, 2021 |
By 340B Matters The drug industry already has some of the highest profit margins of any sector and they’re getting higher for Eli Lilly. U.S. revenues increased by ...
Posted on October 19, 2021 |
By 340B Matters If there were any doubts about just how idiotic Big Pharma’s arguments can be against the 340B Drug Discount Program, look no further than Arkansas where ...
Posted on October 1, 2021 |
By 340B Matters The Department of Health and Human Services has referred six recalcitrant drug companies to the agency Inspector General for civil monetary penalties for denying 340B discounts to ...
Posted on September 8, 2021 |
By 340B Matters Dear Secretary Becerra, On August 1 and September 1, Boehringer Ingelheim and Merck respectively began denying 340B discount pricing to safety-net healthcare providers that use contract pharmacies. This is ...